4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients

Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A53-A53
Hauptverfasser: Toledo Davia, MA, Labrador Andujar, N, Rubio Salvador, AR, Blazquez Romero, C, Torralba Fernandez, L, Jimenez Mendez, C, Prieto Galindo, R, Dominguez Barahona, A, Aguado Barroso, P, Gomez Fernandez, E, Moya Gomez, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of oncological pathologies.Aim and ObjectivesTo analyse whether there is a statistical relationship between these three parameters and to analyse the biomarkers and to analyse their effect on survival.Material and MethodsObservational and retrospective study in patients treated with pembrolizumab and diagnosed with non-small-cell lung cancer (NSCLC) in a tertiary level hospital. Demographic variables (sex and age) were collected, NLR as neutrophil/lymphocyte count, dNLR as neutrophil/leukocyte/neutrophil count and PLR as platelet/lymphocyte count were calculated. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and log-rank test as a hypothesis test. The cut-off points were NLR=5, dNLR=3 and PLR=200. Spearman’s correlation test was used to check the correlation between the three biomarkers (previously the non-normality of the samples was checked by Kolmogorov-Smirnov test).ResultsA total of 74 patients treated with pembrolizumab were registered, 59 men (80,8%) and 14 women, with a median age of 65 [83-37] years. Median neutrophil count was 5.45 [6.1-1.5] x109neut/L, lymphocyte count was 1.45 [3.9-0.2] x109linf/L and platelet count was 174.7 [56.92-1345] x109 platelets/L. Table 1 shows the survival results obtained.Abstract 4CPS-092 Table 1Results of Kaplan-Meier survival method and log-rank test Progression-free survival Overwal survival Median IC95% (months) p LR-t Median IC95% (months) p LR-t NLR5 (n=29) 12,5 (5,1-19,9) 17,4 (9,1-25,6) dNLR3 (n=26) 11,5 (13,7-19,3) 17,09 (8,2-25) PLR200 (n=26) 9,97 (2,86-17,1) 11,31 (3,86-18,79) Spearman’s correlation test showed statistical significance in the relationship between the three biomarkers showing a strong association between them, Spearman’s coefficients obtained are shown: NLR-dNLR 0.934 (p=0), NLR-PLR 0.697 (p=0) dNLR-PLR 0.616 (p=0).Conclusion and RelevanceFor the three biomarkers there are significant differences in survival outcomes for the selected cut-off points, offering prognostic v
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2023-eahp.112